Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) posted its earnings results on Monday. The biopharmaceutical company reported $1.60 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.06, FiscalAI reports. The firm had revenue of $376.71 million during the quarter, compared to the consensus estimate of $358.60 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.
Halozyme Therapeutics Trading Up 3.5%
NASDAQ:HALO traded up $2.27 during midday trading on Monday, hitting $66.39. 1,883,838 shares of the company traded hands, compared to its average volume of 1,720,058. The firm’s fifty day moving average is $65.86 and its 200-day moving average is $68.59. Halozyme Therapeutics has a 12-month low of $47.50 and a 12-month high of $82.22. The firm has a market capitalization of $7.87 billion, a P/E ratio of 26.66, a P/E/G ratio of 0.26 and a beta of 0.89. The company has a current ratio of 4.66, a quick ratio of 3.66 and a debt-to-equity ratio of 43.89.
Insider Activity at Halozyme Therapeutics
In related news, COO Cortney Caudill sold 8,857 shares of the stock in a transaction on Tuesday, March 10th. The stock was sold at an average price of $67.64, for a total transaction of $599,087.48. Following the sale, the chief operating officer owned 7,055 shares in the company, valued at approximately $477,200.20. This represents a 55.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction on Friday, May 1st. The shares were sold at an average price of $63.48, for a total value of $103,155.00. Following the sale, the director owned 38,498 shares in the company, valued at $2,443,853.04. The trade was a 4.05% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 90,482 shares of company stock worth $6,073,942. Company insiders own 2.50% of the company’s stock.
Institutional Trading of Halozyme Therapeutics
Analyst Ratings Changes
A number of research analysts have recently commented on the company. HC Wainwright increased their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Wednesday, April 29th. Wall Street Zen downgraded Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Saturday, February 21st. Wells Fargo & Company increased their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the company an “equal weight” rating in a research report on Thursday, February 19th. Benchmark increased their price target on Halozyme Therapeutics from $75.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, February 19th. Finally, Weiss Ratings lowered Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a report on Tuesday, February 24th. Six analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $79.11.
Read Our Latest Research Report on Halozyme Therapeutics
About Halozyme Therapeutics
Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.
The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.
Featured Stories
- Five stocks we like better than Halozyme Therapeutics
- Before the Moon Base Gets Built, These 4 Companies Win
- Industrial Buybacks: Top Homebuilding Supplier Leads Buyback Increases
- 3 Stocks That Win If Inflation Surprises to the Downside
- MercadoLibre Boldly Invests in Growth: Discount Deepens
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
